| Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 13194* | 2021 |
| Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity J Tsai, JT Lee, W Wang, J Zhang, H Cho, S Mamo, R Bremer, S Gillette, ... Proceedings of the National Academy of Sciences 105 (8), 3041-3046, 2008 | 1590 | 2008 |
| Customer relationship dynamics: service quality and customer loyalty in the context of varying levels of customer expertise and switching costs SJ Bell, S Auh, K Smalley Journal of the Academy of Marketing Science 33 (2), 169-183, 2005 | 849 | 2005 |
| PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression KHT Paraiso, Y Xiang, VW Rebecca, EV Abel, YA Chen, AC Munko, ... Cancer research 71 (7), 2750-2760, 2011 | 639 | 2011 |
| Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases KSM Smalley, NK Haass, PA Brafford, M Lioni, KT Flaherty, M Herlyn Molecular cancer therapeutics 5 (5), 1136-1144, 2006 | 522 | 2006 |
| Adhesion, migration and communication in melanocytes and melanoma NK Haass, KSM Smalley, L Li, M Herlyn Pigment cell research 18 (3), 150-159, 2005 | 510 | 2005 |
| A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? KSM Smalley International journal of cancer 104 (5), 527-532, 2003 | 456 | 2003 |
| Life ins't flat: Taking cancer biology to the next dimension KSM Smalley, M Lioni, M Herlyn In Vitro Cellular & Developmental Biology-Animal 42, 242-247, 2006 | 387 | 2006 |
| Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas KSM Smalley, M Lioni, MD Palma, M Xiao, B Desai, S Egyhazi, J Hansson, ... Molecular cancer therapeutics 7 (9), 2876-2883, 2008 | 386 | 2008 |
| Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy KHT Paraiso, IV Fedorenko, LP Cantini, AC Munko, M Hall, VK Sondak, ... British journal of cancer 102 (12), 1724-1730, 2010 | 374 | 2010 |
| The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma F Meier, B Schittek, S Busch, C Garbe, K Smalley, K Satyamoorthy, G Li, ... Front Biosci 10 (2986–3001), 2986-3001, 2005 | 335 | 2005 |
| Rewired ERK-JNK signaling pathways in melanoma P Lopez-Bergami, C Huang, JS Goydos, D Yip, M Bar-Eli, M Herlyn, ... Cancer cell 11 (5), 447-460, 2007 | 332 | 2007 |
| Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin … ZJ Liu, M Xiao, K Balint, KSM Smalley, P Brafford, R Qiu, CC Pinnix, X Li, ... Cancer research 66 (8), 4182-4190, 2006 | 323 | 2006 |
| Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885 AJ King, DR Patrick, RS Batorsky, ML Ho, HT Do, SY Zhang, R Kumar, ... Cancer research 66 (23), 11100-11105, 2006 | 301 | 2006 |
| An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells KSM Smalley, R Contractor, NK Haass, AN Kulp, GE Atilla-Gokcumen, ... Cancer research 67 (1), 209-217, 2007 | 276 | 2007 |
| The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when … NK Haass, K Sproesser, TK Nguyen, R Contractor, CA Medina, ... Clinical Cancer Research 14 (1), 230-239, 2008 | 271 | 2008 |
| CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations KSM Smalley, M Xiao, J Villanueva, TK Nguyen, KT Flaherty, R Letrero, ... Oncogene 28 (1), 85-94, 2009 | 246 | 2009 |
| The role of altered cell–cell communication in melanoma progression NK Haass, KSM Smalley, M Herlyn Journal of molecular histology 35, 309-318, 2004 | 228 | 2004 |
| A brief history of melanoma: from mummies to mutations VW Rebecca, VK Sondak, KSM Smalley Melanoma research 22 (2), 114-122, 2012 | 227 | 2012 |
| Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma GT Gibney, JL Messina, IV Fedorenko, VK Sondak, KSM Smalley Nature reviews Clinical oncology 10 (7), 390-399, 2013 | 222 | 2013 |
John KoomenSenior Member, Moffitt Cancer CenterBestätigte E-Mail-Adresse bei moffitt.org
